MENLO PARK, Calif., Jan. 4 /PRNewswire/ -- ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, announced today the appointment of William A. Albright, Jr. as the company's Chief Financial Officer. Mr. Albright has more than 20 years of medical device and biotechnology experience in both finance and executive management, most recently as Chief Financial Officer and Senior Vice President, Finance and Operations of Xenogen Corporation, which was acquired by Caliper Life Sciences in 2006.

"It is with great pleasure that we welcome Bill to ForteBio," stated Winnie H. Wan, Ph.D., President and Chief Executive Officer. "His extensive experience and proven track record, both in commercial operations and equity financings, will be great assets to ForteBio as we continue to penetrate the biotechnology and pharmaceutical laboratory markets with our Octet System for label-free, real-time analysis of molecular interactions."

At Xenogen, a leading provider of novel in-vivo imaging (bioluminescence) systems, Mr. Albright raised more than $60M in financings within 13 months, including a $30M initial public offering. After helping to expand the sales force and manufacturing operations, and significantly increasing the company's valuation, he led the merger with Caliper Life Sciences, which was completed in August 2006. Mr. Albright's expertise in general management and organization of growth and turn-around companies includes executive positions at FlowMedica, Inc., as Chief Executive Officer; Nexell Therapeutics, Inc., as President and Chief Executive Officer; and as Chief Financial Officer at LocalMed, Inc., Connetics Corporation and ChemTrak, Inc.

At ForteBio, Mr. Albright will be responsible for the company's finance organization, managing the company's operations functions, raising additional capital and working with the CEO on major business transactions. He received an MBA from Harvard Business School and holds both his BS and MS degrees in Biological Sciences from Stanford University.

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com .

     Contact:  Winnie H. Wan, Ph.D.
               President & Chief Executive Officer
                ext 112
               

SOURCE ForteBio, Inc.